Condition: Acute Myeloid Leukemia · Sponsor: Shenzhen Geno-Immune Medical Institute
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML. The study also aims to learn more about the function of the universal CAR T cells and their persistency in AML patients.
This description comes directly from the study's public registry record.
Lung-Ji Chang, Ph.D · +86 0755-86573763 · c@szgimi.org
Ying Deng · +86 0755-86573763 · ying.deng@szgimi.org
Always discuss trial participation with your own doctor first.
| Shenzhen Geno-Immune Medical Institute | Shenzhen, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05995041